Background: Immune checkpoint inhibitors (ICI) have shown promising prospects in
gastroesophageal junction (G/GEJ) cancer immunotherapy, many clinical trials have been …

Purpose This study aimed to clarify the current knowledge on the use of immunotherapy in
patients with advanced gastric (G)/gastroesophageal (GEJ) cancers. Materials and methods …

Background: Current therapeutic options have limited efficacy for patients with advanced
gastric or gastroesophageal junction cancer. Immune checkpoint inhibition now has been …

Despite the application of conventional therapies, the prognosis of advanced gastric cancer
(GC) or gastroesophageal junction cancer (GEJC) is still poor. In recent years, immune …

Background Standard treatment options for patients with advanced gastric or
gastroesophageal junction cancer (GC/GEJC) are associated with limited efficacy and some …

Background: Gastric carcinoma (GC) is the fourth most common cause of cancer-related
death worldwide. Most patients are diagnosed at later stage, because of few treatment …

Recent breakthrough results from immune checkpoint inhibitors (ICI) have paved the way to
a new era of cancer immunotherapy. In particular, inhibition of programmed death-1 (PD …

Gastric cancer is a leading cause of cancer-related death worldwide. Recent evidence
suggests that gastric cancer is a complex and heterogenous disease with emerging …

Immune checkpoint inhibition is a new standard of targeted therapy in the treatment of
advanced or metastatic gastric cancer (GC) and is represented in various combinations with …

Background While the efficacy of immune checkpoint inhibitors (ICIs) is increasingly
recognized in advanced gastric cancer (aGC), overall survival (OS) has not been …